CASI Pharmaceuticals is a biopharmaceutical company dedicated to the commercialization of innovative therapeutics and pharmaceutical products, particularly focusing on the treatment of leukemias and lymphomas. Its product portfolio includes several key injections, such as EVOMELA, which is used as a conditioning treatment prior to autologous stem cell transplants for patients with multiple myeloma. Other notable products in its pipeline include CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. CASI leverages its expertise and resources in China to develop and commercialize these products, with the majority of its revenue generated from sales of EVOMELA. The company aims to build a robust pipeline through strategic business development transactions that enhance its market presence in China and beyond.
Precision Autoimmune Therapeutics is a clinical-stage innovative drug development company focused on precision therapeutics for patients with autoimmune and inflammatory diseases.
Juventas is a developer of innovative immune cell therapeutic drugs aimed at treating malignant hematological neoplasms, including leukemia and lymphoma. The company has had its first investigational new drug application for the cell therapeutic product CNCT19 accepted by the National Medical Products Administration. Juventas is committed to developing a comprehensive product pipeline that focuses on advancing immune cell therapies and accelerating innovation in this field, thereby providing effective treatment options for patients suffering from these serious conditions.
Miikana Therapeutics
Acquisition in 2006
Miikana Therapeutics is a private held biotechnology company. It is a biopharmaceutical company focuses on the discovery and development of medicines for the treatment of cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.